Infliximab and prednisolone: Too much of a good thing?

Hepatology

Volumn 39, Issue 6, 2004, Pages 1488-1490

  McClain, Craig J ^a,b   Hill, Daniell B ^a   Barve, Shirish S ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; INFLIXIMAB; MISOPROSTOL; PENTOXIFYLLINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL LIVER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HEPATITIS, ALCOHOLIC; HUMANS; PREDNISOLONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2542527027     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20267     Document Type: Editorial

References (24)

1. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. HEPATOLOGY 1989;9:349-351.
2. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259.
3. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. HEPATOLOGY 1991;13:267-276.
4. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205-219.
5. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. HEPATOLOGY 1997;26:143-146.
6. Laso FJ, Lapena P, Madruga JI, San Miguel JF, Orfao A, Iglesias MC, Alvarez-Mon M. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997;21:1226-1231.
7. McClain CJ, Barve S, Barve S, Deaciuc I, Hill DB. Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res 1998;22:248S-252S.
8. Hanck C, Rossol S, Bocker U, Tokus M, Singer MV. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 1998;33:606-608.
9. Bhagwandeen BS, Apte M, Manwarring L, Dickeson J. Endotoxin induced hepatic necrosis in rats on an alcohol diet. J Pathol 1987 152:47-53.
10. Honchel R, Ray MB, Marsano L, Cohen D, Lee E, Shedlofsky S, McClain CJ. Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 1992;16:665-669.
11. Nanji AA, Zhao S, Sadrzadeh SM, Waxman DJ. Use of reverse transcription-polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods. HEPATOLOGY 1994;19:1483-1487.
12. Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. HEPATOLOGY 1995;21:1304-1309.
13. Nanji AA, Zhao S, Sadrzadeh SMH, Sannenbert AJ, Tahan SR, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol fed rats. Alcohol Clin Exp Res 1994;18:1280-1285.
14. Sadrzadeh SM, Nanji AA. The 21-aminosteroid 16-desmethyl tirilazad mesylate prevents necroinflammatory changes in experimental alcoholic liver disease. J Pharmacol Exp Ther 1998;284:406-412.
15. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease. Proc Soc Exp Biol Med 1994 205:243-247.
16. Adachi Y, Bradford B, Gao W, Bojes H, Thruman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. HEPATOLOGY 1994;20:453-460.
17. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor-a attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. HEPATOLOGY 1997;26:1530-1537.
18. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luser MI, et al. Essential role of tumor necrosis factor a in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952.
19. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet M-A, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. HEPATOLOGY 2004;39:1390-1397.
20. Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001;166:130-136.
21. Akerman PA, Cote PM, Yang SQ, McClain CJ, Nelson S., Bagby G, et al. Long-term ethanol consumption alters the hepatic response to the regenerative effects of tumor necrosis factor-alpha. HEPATOLOGY 1993;17:1066-1073.
22. Menon KVN, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-260.
23. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
24. Lee KS, Cottam HB, Houglum K, Wasson DB, Carson D, Chojkier M. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol 1997;273(5 Pt 1):G1094-G1100.